Drug Profile

Molnupiravir - Emory University/Georgia State University/Merck & Co/Ridgeback Biotherapeutics

Alternative Names: EIDD-2801; LAGEVRIO; MK-4482; Molxvir; Movfor

Latest Information Update: 14 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Emory University; Georgia State University
Developer Emory University; Hetero Labs; Merck & Co; Merck Sharp & Dohme; Ridgeback Biotherapeutics
Class Antivirals; Esters; Hydroxylamines; Pyrimidinones; Ribonucleosides; Small molecules
Mechanism of Action Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed COVID 2019 infections
Phase II Respiratory syncytial virus infections
Phase I Influenza virus infections; Renal failure
No development reported Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Middle East respiratory syndrome coronavirus; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis

05 Dec 2024 Phase-III clinical trials in COVID-2019 infections in USA (PO) (NCT06667700)
30 Oct 2024 Merck plans a phase III MOVe-NOW trial for COVID-2019 infections (PO, Tablet) in December 2024 (NCT06667700)
16 Oct 2024 Pharmacodynamics and efficacy data from a phase II/III trial in COVID-2019 infections presented at the IDWeek 2024 (IDW-2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com